Back to Insights
DSO Strategy
April 2026
·
9 min read

DSO vs. Private Equity Acquisition: What's the Difference

Most dentists conflate DSOs and private equity. They're related — but the deal mechanics, multiples, and post-close experience are not the same.

AMK
Andrew Killgore, D.M.D., F.A.G.D.
Dental Entrepreneur · Investor · Advisor
Key Takeaways
  • DSO is an entity type; private equity is a funding structure — most large DSOs today are PE-backed, but not all PE-backed buyers operate through a traditional DSO model
  • Three buyer structures compared: traditional DSO, PE-backed platform, and family office/non-PE buyer
  • Rollover equity (10–30%) is common in PE-backed acquisitions but rare in traditional DSO deals
  • Post-close autonomy varies more by platform maturity and integration model than by buyer label
  • The right buyer type depends on your goals: immediate liquidity, second bite of the apple, clinical autonomy, or operational relief

When dental practice owners start getting calls from buyers, the terminology comes fast: DSO, PE-backed platform, family office, strategic buyer, rollup. Most dentists use "DSO" and "private equity" interchangeably. That conflation is understandable — the majority of active DSO buyers today are backed by private equity — but it obscures meaningful differences in deal structure, post-close autonomy, and long-term financial outcome that can be worth hundreds of thousands of dollars.

I sold Afinia Dental Group to a PE-backed buyer in 2021. What I learned in that process is that the label on the buyer matters less than the specific terms of the deal — but understanding the landscape first gives you the leverage to negotiate those terms intelligently.

This article breaks down the three main buyer categories, compares them across the dimensions that actually affect your life after close, and offers a decision framework for matching your goals to the right buyer type.

The Misconception: DSO and PE Are Not the Same Thing

A DSO — Dental Service Organization — is an entity that manages the non-clinical operations of dental practices. It handles billing, HR, marketing, supply purchasing, and compliance while the clinical team operates under a separate professional corporation. DSOs range from small regional groups with five locations to national platforms with hundreds.

Private equity is a funding structure, not a buyer type. A PE firm raises capital from institutional investors, deploys it to acquire businesses, improves their operations and financial profile, and sells them at a higher multiple within a defined hold period — typically five to seven years. Most large DSOs today are PE-backed, meaning a PE firm owns the DSO and uses it as the acquisition vehicle.

But not all PE-backed buyers operate through a traditional DSO structure. Some are dental holding companies that acquire practices directly and integrate them into a portfolio without a DSO management layer. Some are family offices — private investment vehicles for wealthy families — that are doing dental rollups without institutional PE backing. And some large DSOs have reached a scale where they operate independently of PE ownership.

The practical implication: when you get an offer, asking "is this a DSO?" is less useful than asking "who owns the buyer, what is their hold period, and what happens to my practice at their next exit?"

Comparison: The Three Buyer Structures

DimensionSell to a DSOSell to a PE-backed PlatformSell to a Family Office / Non-PE Buyer
**Ownership structure**DSO holds management contract; you retain clinical PCPE firm owns DSO or platform; you sell equity in practiceFamily office or independent group owns practice outright
**Typical buyer profile**Regional or national DSO (Heartland, Aspen, Pacific Dental, etc.)PE-backed dental rollup platform (new or emerging)High-net-worth family or independent dental group
**EBITDA multiple range**4x–7x for single locations; 6x–10x for multi-location groups5x–10x+ depending on platform stage and practice profile3x–6x; typically lower multiples but more flexible terms
**Deal structure**Cash at close + possible earnout; rollover equity uncommonCash + rollover equity (10–30%) common; earnout possibleCash at close; rollover equity rare
**Post-close clinical autonomy**Varies widely; large DSOs tend to standardize protocolsVaries; early-stage platforms often preserve autonomy to attract sellersGenerally high; family offices often hands-off on clinical
**Post-close operational integration**High integration; DSO management layer takes over HR, billing, marketingModerate to high; depends on platform's integration modelLow to moderate; often retain existing staff and systems
**Rollover equity availability**Uncommon; most DSOs offer cash-onlyCommon; PE platforms use rollover equity to align seller incentivesRare; most family offices prefer clean cash transactions
**Exit horizon**Ongoing; DSO may hold indefinitely or sell to larger DSO5–7 year PE hold period; second bite of the apple at PE exitIndefinite; family offices may hold for decades

The "Second Bite" — Why Rollover Equity Changes the Math

The most significant structural difference between a PE-backed acquisition and a traditional DSO sale is rollover equity. When a PE-backed platform acquires your practice, they will typically ask you to roll 10–30% of your sale proceeds back into equity in the acquiring platform. This is not charity — it is alignment. The PE firm wants you to have skin in the game so you continue to run the practice well during their hold period.

The upside is that when the PE firm exits — selling the platform to a larger PE firm or taking it public — your rolled equity participates in that second transaction. If the platform's EBITDA multiple expands between your sale and their exit (which is the PE firm's entire business model), your rolled equity can return two to four times its value.

The downside is illiquidity and risk. Rolled equity is not cash. If the platform underperforms or the PE firm takes on excessive debt, your rollover stake can be worth significantly less than what you put in. PKF O'Connor Davies notes that sellers should treat rollover equity as a speculative investment, not a guaranteed return.

Decision Framework: Which Structure Fits Your Goals

The right buyer type depends on what you are optimizing for — not what the market is currently paying. Here is a simplified framework:

If your primary goal is maximum immediate liquidity: A large established DSO or a PE-backed platform offering a high cash-at-close percentage is your best path. Rollover equity is negotiable — you can often reduce the rollover requirement in exchange for a slightly lower headline multiple.

If your primary goal is a second bite of the apple: A PE-backed platform in its early growth phase is the right target. The multiple may be lower than a mature DSO's offer, but the rollover equity in a platform that is three years into a seven-year hold has more room to appreciate than equity in a platform that is two years from its exit.

If your primary goal is preserving clinical autonomy post-close: A family office or a smaller regional DSO that has not yet standardized clinical protocols will give you more day-to-day independence. The trade-off is typically a lower multiple and no rollover equity upside.

If you are a multi-location operator looking to scale further: A PE-backed platform that is actively acquiring may offer you an operational role — Chief Dental Officer, regional director — in addition to the sale. This is a different kind of transaction than a clean exit. [See our guide to what DSO buyers actually look for](/blog/what-dso-buyers-look-for) for more on how buyers evaluate operators versus pure practice sellers.

What Changes After Close

The dimension most sellers underestimate is the post-close operational reality. The deal terms are negotiated over weeks. The post-close experience lasts years.

In a large DSO acquisition, the management layer arrives quickly. Billing transitions to the DSO's platform. HR policies change. Marketing is centralized. Supply purchasing is standardized. The clinical team may stay intact, but the administrative infrastructure around them will look different within six to twelve months. This is not inherently bad — many practice owners find the operational relief significant — but it is a real change, and sellers who did not anticipate it often experience it as a loss of control rather than a benefit.

When I sold Afinia in 2021, the deal included meaningful rollover equity but I exited from operations entirely — I didn't sign a long earnout or stay on as a clinical partner. What I've seen in the years since is that post-close outcomes vary a lot from practice to practice — some of the locations are running better than they did under me, others have struggled. The integration playbook the buyer brings, and how well the local clinical leadership adapts to it, matters more than most sellers realize at the LOI stage. Industry observers note that early-stage PE-backed dental platforms tend to leave more operational latitude in the first 12–24 months while they're still building infrastructure, and tighten as the platform matures — but how that lands in any specific practice depends heavily on the people involved.

In a family office acquisition, post-close operations often look nearly identical to pre-close — for better and worse. The family office gets the practice's cash flow; the seller gets a clean exit. There is typically no platform infrastructure to absorb operational complexity, which means the seller's systems need to be strong enough to run without the seller before close.

For a deeper look at how to prepare your practice for any of these buyer types, see [our complete guide to selling a dental practice to private equity](/blog/how-to-sell-dental-practice-private-equity) and [our 2026 dental practice valuation multiples breakdown](/blog/dental-practice-valuation-multiples-2026).

The Bottom Line

DSO and private equity are not synonyms. Most DSOs are PE-backed, but the deal mechanics, post-close experience, and long-term financial outcomes differ meaningfully across buyer types. The right buyer for your practice depends on what you are optimizing for — immediate liquidity, a second bite of the apple, clinical autonomy, or operational relief — and no buyer type is universally superior.

The most important thing you can do before engaging any buyer is to understand your own goals clearly enough to evaluate an offer against them. If you are not sure what you are optimizing for, that is the first conversation to have — not with a broker, but with someone who has been on your side of the table.

If you are a dental practice owner starting to think through a sale, [reach out for a free consultation](/contact). The earlier you start the conversation, the more options you have.

Work With Andrew

Ready to put these ideas into practice?

Schedule a complimentary 30-minute consultation. Andrew will assess your specific situation and give you a clear path forward — no obligation, no sales pitch.

Book a Free Consultation
AMK
Andrew Killgore, D.M.D., F.A.G.D.
Dental Entrepreneur · Investor · Advisor

Andrew Killgore is the founder of AMK Consulting LLC and the former founder of Afinia Dental Group — the largest dental group in the Cincinnati region, which he built and sold in a successful DSO exit in 2021. With 20+ years in dentistry, Andrew now advises dental entrepreneurs on practice systemization, DSO readiness, and achieving business freedom.

Frequently Asked Questions